Cough Science News
Find all editions of Cough Science News below and get access to the latest cough science developments, publications, and interviews with cough experts.
Find all editions of Cough Science News below and get access to the latest cough science developments, publications, and interviews with cough experts.










This month’s roundup explores placebo effects in RCC trials, the role of interoception in chronic cough, and the cost burden of persistent symptoms, plus insights from Dr. Nadia Giannetti.

New key cough science publications, Actigraph x Hyfe partnership and more

This year marked significant progress in cough monitoring, solidifying cough as a valuable biomarker in diverse therapeutic areas

New findings on refractory chronic cough (RCC), pulmonary tuberculosis, and pulmonary fibrosis. Plus latest white papers by Hyfe.

Cough Science News Oct 1 - new studies on cough-related stress urinary incontinence, COVID-19 detection in vaccinated adults, and the effectiveness of anti-reflux surgery for chronic cough. Plus, expert discussions from Hyfe's Cough Science Forum and the latest on FDA regulations for cough monitoring technologies

Cough Science News Oct 1 - new studies on cough-related stress urinary incontinence, COVID-19 detection in vaccinated adults, and the effectiveness of anti-reflux surgery for chronic cough. Plus, expert discussions from Hyfe's Cough Science Forum and the latest on FDA regulations for cough monitoring technologies

Cough Science News, August 2024 - Explore studies on cough variability, acute cough duration, and the cost burden of chronic cough. Plus, discover the world’s most comprehensive collection of cinematic coughs and upcoming events in cough science

CougH Science News July 2024 - latest in cough science. Insights on cough detection algorithms, pulmonary fibrosis, asthma diagnosis from cough sounds, and more. Plus, watch expert discussions and stay updated on upcoming events

Hyfe Cough Science News, June 2024. Latest research on cough in fibrotic ILD, high-dose inhaled corticosteroids for chronic cough, and family physicians’ approaches to managing chronic cough. Plus, insights from leading researchers and upcoming events

Cough Science News May 2024 - studies on cough monitoring for COVID-19 surveillance, the effectiveness of codeine for chronic cough, factors in refractory cough in IPF, and more. Plus, insights from researchers and upcoming events

Hyfe Cough Science News, March 2024 - insights on chronic cough management in the UK, common triggers in cough hypersensitivity, and a review of treatments for refractory cough. Plus, expert Q&A and upcoming cough science events.

Here's What's Inside
Key Takeaway: In this 12-week double-blind study, 32 patients with COPD were monitored at home using a stationary bedside device that tracked nighttime cough frequency. The system flagged 59% of exacerbations, with 26% detected before symptom onset, providing a median lead time of 6 days. Importantly, the system required no patient input and was rated as unobtrusive and acceptable by nearly all participants.
Why It Matters: Early intervention is crucial in COPD, but existing tools rely on patient-reported data and have high false alert rates. This study shows that passive cough monitoring offers a low-burden, high-specificity alternative. While 30% of exacerbations occurred without increased coughing, this approach still offers a promising foundation for future remote monitoring systems in COPD.
Key Takeaway: In this multicentre observational study of 248 patients with progressive pulmonary fibrosis (PPF), over 75% reported experiencing cough, a symptom that significantly affected health-related quality of life. Cough severity, measured by VAS and LCQ scores, was associated with poorer lung function and reduced six-minute walk distances, highlighting its clinical importance beyond breathlessness alone.
Why It Matters: Cough is common in PPF and contributes meaningfully to the disease burden, yet it remains under-recognised and inadequately managed. This study highlights the need to treat cough as a key symptom in PPF care and to prioritise it in future treatment approaches and clinical research.
Key Takeaway: This expert review outlines the ongoing challenges in managing chronic cough and the emerging shift from traditional anatomical diagnoses to a treatable traits approach. Despite the growing recognition of cough hypersensitivity as a core mechanism, there are still no widely approved drug treatments. Promising candidates like P2X3 antagonists show potential, but high placebo responses and outdated endpoints have stalled progress.
Why It Matters: Chronic cough is increasingly seen as a distinct disease, but clinical trials and treatment strategies have struggled to keep up. The authors call for better-designed trials, modern patient-reported outcomes, and wider adoption of continuous cough monitoring to address cough’s variability. They also highlight the urgent need for clinician and patient education to improve diagnosis, management, and access to care.
As continuous cough monitoring enters clinical trials, this whitepaper lays out the urgent ethical and operational questions - and the technologies that could solve them.




